1 / 8

Stock Analyzation: Pfizer's acqusition King Pharmaceuticals

Given in a lecture for Corporate Finance class at the HTW, Berlin.

K_Navita
Download Presentation

Stock Analyzation: Pfizer's acqusition King Pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pfizer to Purchase King Pharmaceuticals News from October 14, 2010 – Pharmtech Newsletter Magda Neumann – Alina Sachapow – Kasey Navita Phifer [ January 4, 2011 ] www.kNavita.com

  2. News Details • Pfizer produces pharmaceuticals (Viagra, Lipitor, Celebrex) • Announcement of Purchase: Oct. 12, 2010 • $3.6 billion cash • Pfizer paid $14.25 per share (40% higher than closing price) • Top two Pfizer drug patents (Lipitor & Xalatan) expire 2011 • Purchased Wyeth in early 2009 Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  3. Financials of the News Numbers in billions of USD*Share Price NOT in billions Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  4. Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  5. Theoretical Linkages • Chapter 7 • Technical analysis - Trends, volume, OBV, MACD, SMA • Fundamental analysis - Background information • Valuation by comparables Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  6. Conclusion • Purchase of King less dramatic than Wyeth • Tactical desicion regarding expiring patents, falling stock prices & growing competition • Stock price still low (compared to $50 earlier) Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  7. Resources • Brealey/Myers/Marcus, Fundamentals of Corporate Finance, 6th Edition, McGraw-Hill, 2009 [Chapter 7] • http://www.wikinvest.com/stock/Pfizer_(PFE)/Generic%20Competition (accessed 21.11.2010) • http://de.finance.yahoo.com/echarts?s=PFE#symbol=pfe;range=2y;compare=;indicator=volume;charttype=area;crosshair=on;ohlcvalues=0;logscale=off;source=undefined; (accessed 15.11.2010) • http://www.wikinvest.com/stock/Pfizer_(PFE)/Generic%20Competition (accessed 21.11.2010) • http://drugdelivery.pharmaceutical-business-review.com/news/pfizers_q4_revenue_decreases_290109 (accessed 21.11.2010) • http://www.wikinvest.com/stock/Pfizer_(PFE)/Data/Key_Metrics (accessed 21.11.2010) • http://de.finance.yahoo.com/echarts?s=PFE#chart8 (accessed 15.11.2010) • http://www.marketwatch.com/investing/stock/PFE/charts?countryCode=US&submitted=true&intflavor=advanced&origurl=%2Ftools%2Fquotes%2Fintchart.asp&time=9&freq=1&comp=Enter%20Symbol(s)%3A&compidx=aaaaa~0&compind=aaaaa~0&uf=7168&ma=1&maval=50&lf=1&lf2=4&lf3=8&type=2&size=2&optstyle=1013 (accessed 15.11.2010) • http://www.investopedia.com/university/technical/ (accessed 14.11.2010)

  8. Thank You for Your Attention! Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ] www.kNavita.com

More Related